Our results indicate that more comprehensive co-analyses of SETD2 mutation and H3K36me3 levels are warranted in future studies, and will likely be essential to fully understand their interplay with tumor phenotypes and patient outcome. This evidence concerns the gene SETD2 and neoplasm.